Valsalva blood pressure drop and obstruction of the heart's outflow tract

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Researchers prospectively collected systolic blood pressure (SBP) waveforms and echocardiographic left ventricular outflow tract gradient (LVOTG) measurements from adults with obstructive and non-obstructive hypertrophic cardiomyopathy. Participants underwent provocation tests including Valsalva while continuous non-invasive hemodynamic monitoring recorded SBP waveform changes. The study analyzes correlations between SBP waveform patterns and LVOTG to determine whether SBP dynamics can indicate presence or severity of obstruction. Results were explored for use in different clinical scenarios, such as follow-up monitoring and provocation testing.

Why it matters

Who can join: the full rules

Inclusion Criteria:1: ① Age ≥ 18 years

2: ② Diagnosed with hypertrophic cardiomyopathy (HCM) by echocardiography, with or without left ventricular outflow tract obstruction

3: ③ Conscious and mentally competent, able to understand and voluntarily sign the informed consent form

4: ④ Able to cooperate with the completion of provocation tests, non-invasive dynamic hemodynamic monitoring, and relevant follow-up examinations.

\-

Exclusion Criteria:

* 1: ① Age ≤ 18 years, or pregnant/lactating patients

  2: ② Presence of other organic heart or great vessel diseases that cause left ventricular outflow tract obstruction, such as severe aortic stenosis, congenital subaortic membrane, etc.

  3: ③ Complicated with persistent atrial fibrillation or other severe arrhythmias that may affect the accuracy of hemodynamic monitoring

  4: ④ Previous history of interventional or surgical therapy for left ventricular outflow tract obstruction, including septal ablation or myectomy

  5: ⑤ Patients with other conditions considered inappropriate by the investigators (e.g., those with absolute or relative contraindications to provocation tests)

  6: ⑥ Patients currently participating in other clinical studies.

Where it's running

• Zhongshan Hospital
  Shanghai, Shanghai Municipality, China Recruiting

Study contacts

• Study coordinator: Ziqing Yu, PhD
• Email: yu.ziqing@zs-hospital.sh.cn
• Phone: +86 18833221133

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Transitioning from mavacamten to aficamten in obstructive HCM

  This study tests whether switching from mavacamten to aficamten is feasible and safe for people with obstructive hypertrophic cardiomyopathy who are already on mavacamten.

  Recruiting Phase 4 Oregon Health and Science University · Kansas City, Missouri and 1 other locations · NCT07600177

• 68Ga-NI-FAPI-04 PET/CT imaging to detect fibroblast activation in cancer, fibrotic, and heart diseases

  This test will see if an injected PET tracer called 68Ga-NI-FAPI-04 can better show fibroblast activation in people with tumors, pulmonary fibrosis, certain autoimmune vascular diseases, hypertrophic cardiomyopathy, or other cardiovascular conditions.

  Recruiting Phase 1/2 Peking Union Medical College Hospital · Beijing, Beijing Municipality · NCT07464132

• Understanding why AF happens and is harder to treat in hypertrophic cardiomyopathy

  We’re testing how heart electrical signals and advanced imaging relate to atrial fibrillation in people with hypertrophic cardiomyopathy to see if treatments can be improved.

  Recruiting Guy's and St Thomas' NHS Foundation Trust · London · NCT07454135

• UK multicentre hypertrophic cardiomyopathy registry

  This project collects health information from adults with hypertrophic cardiomyopathy across UK NHS hospitals to see which treatments and tests work best for different patients.

  Recruiting University of Manchester · Manchester · NCT07381894

• Multimodal analysis of heart biopsy samples

  This project will take one extra small heart biopsy during a clinically needed procedure to test whether detailed molecular and immune analyses can find disease-specific signatures in adults with cardiomyopathies, myocarditis, cardiac amyloidosis, or after heart transplant.

  Recruiting University Hospital, Essen · Essen, North Rhine-Westphalia · NCT07359690

• T1 mapping to characterize heart tissue in common heart diseases

  This project tests whether T1 mapping MRI scans, including dye-free native T1, can define normal and disease-specific heart tissue values for adults with various heart conditions.

  Recruiting Chinese Academy of Medical Sciences, Fuwai Hospital · Beijing, Beijing Municipality · NCT07354646

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.